I last wrote here several months ago about the sodium channel (NaV1.8) inhibitor VX-548 (now known as suzetrigine), which is ...
In a report released today, Gena Wang from Barclays maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price ...
NEW YORK, NY / ACCESSWIRE / January 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
ORG Partners LLC boosted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 108.2% ...
International Assets Investment Management LLC lowered its position in shares of Vertex Pharmaceuticals Incorporated ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor ...
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price objective cut by Wells Fargo & Company from $555.00 to ...
ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 ...
Fulton Bank N.A. decreased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 5.6% ...
The increasing adoption of e-invoicing globally and the ongoing enterprise resource planning (ERP) migration super cycle present multi-year growth opportunities for Vertex. As companies shift to ...
Vertex, Inc. (NASDAQ:VERX – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the thirteen research firms that are covering the company, MarketBeat.com reports. Four ...
Vertex, Inc. (NASDAQ:VERX – Get Free Report)’s stock price fell 4.7% on Friday .The stock traded as low as $50.56 and last traded at $50.70. 428,997 shares traded hands during mid-day trading ...